Roche oncology VP to take the reins at Foundation Medicine

Perettie has helped lead several oncology product launches for both Roche and Genentech, including in breast cancer and hematology. (Pixabay)

Roche’s senior VP of global oncology product strategy, Cindy Perettie, is jumping over to become the next CEO of Foundation Medicine, which the Big Pharma acquired last year through a $2.4 billion buyout.

Perettie will succeed Troy Cox, effective Feb. 4, to take the reins for what Cox describes as the next phase of growth for the genomic diagnostic developer and Fierce 15 company.

“As we look ahead, the advancements across our molecular information portfolio position the company to continue to lead in precision oncology and Cindy is well poised to accelerate our work to bring these advances forward and transform cancer care for patients,” Cox said in a statement.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“My time at Foundation Medicine has been one of the most rewarding of my career. The mission, the people, and the impressive progress we have made together has been life-changing for me. I am grateful to carry that with me into my next chapter,” he added.

RELATED: Roche inks $2.4B deal to buy out Foundation Medicine

Perettie has helped lead several oncology product launches for both Roche and Genentech, including in breast cancer and hematology. She began at Genentech in 2004 as a program team leader for Avastin, focused on lung cancer, breast cancer, gastrouterine cancer and melanoma. Since then, she’s served as VP of global regulatory operations and regional head of Europe, Middle East and Africa operations.

RELATED: FierceBiotech’s 2012 Fierce 15 | Foundation Medicine

Perettie also took a hiatus from Genentech in 2012, joining the Sarah Cannon Research Institute as president of global development innovations, where she helped lead its cancer-focused contract research organization business.

Suggested Articles

An FDA panel voted against clearance for Neuronix's transcranial magnetic stimulation device, which targets the brain’s memory and learning centers.

A toilet seat monitoring system aims to spot the signs of heart failure in the privacy of the home, with the goal of lowering hospital readmissions.

The proceeds will push its lead asset, repotrectinib, into phase 2 studies and to advance a pair of earlier-stage programs in advanced solid tumors.